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Summary:  1 
Bipolar disorder (BPD) is a highly heritable polygenic disorder. Recent enrichment 2 
analyses suggest that there may be true risk variants for BPD among the expression 3 
quantitative trait loci (eQTL) in the brain.  4 
 5 
Aims: We sought to assess the impact of eQTL variants on BPD risk by combining 6 
data from both BPD genome-wide association study (GWAS) and brain eQTL. 7 
 8 
Method: To detect single-nucleotide polymorphisms (SNPs) that influence expression 9 
levels of genes associated with BPD, we jointly analyzed data from a BPD GWAS 10 
(7,481 cases and 9,250 controls) and a genome-wide brain (cortical) eQTL (193 11 
healthy controls) using a Bayesian statistical method, with independent follow-up 12 
replications. The identified risk SNP was then further tested for association with 13 
hippocampal volume (N=5,775) and cognitive performance (N=342) among healthy 14 
subjects. 15 
 16 
Results: Integrative analysis revealed a significant association between a brain eQTL 17 
rs6088662 in 20q11.22 and BPD (Log Bayes Factor=5.48; BPD p-val=5.85×10-5). 18 
Follow-up studies across multiple independent samples confirmed the association of 19 
the risk SNP (rs6088662) with gene expression and BPD susceptibility 20 
(p-val=3.54×10-8). Further exploratory analysis revealed that rs6088662 is also 21 
associated with hippocampal volume and cognitive performance in healthy subjects. 22 
 23 
Conclusions: Our findings suggest that 20q11.22 is likely a risk region for BPD, 24 
highlighting the informativeness of integrating functional annotation of genetic 25 
variants for gene expression in advancing our understanding of the biological basis 26 
underlying complex diseases such as BPD. 27 
 28 
Declaration of interest: None 29 
30 
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Bipolar disorder (BPD) is a severe, chronic psychiatric disorder with worldwide 1 
lifetime prevalence ranging from 0.5-1.5%.1 BPD is characterized by a variety of 2 
profound mood symptoms including episodes of mania, hypomania and depression, 3 
and is often accompanied by psychotic features and cognitive deficits. To date, there 4 
has been a fair amount of data from family and twin studies to highlight a strong 5 
genetic predisposition for BPD.1 That said, BPD is a highly polygenic disorder that 6 
can vary substantially from population to population. While linkage analyses and 7 
genetic association studies have yielded numerous candidate variants for BPD, only a 8 
few of these have been satisfactorily replicated across independent samples.2,3 9 
With the advances in knowledge of human genetic variations—such as data 10 
generated by the HapMap and 1000-Human-Genome projects and several subsequent 11 
genome-wide association studies (GWASs) by a number of international 12 
collaborators—a wealth of novel susceptible variants for BPD have been reported, 13 
particularly SNPs in CACNA1C, ANK3, ODZ4, NCAN and TRANK1.4-8 These 14 
GWAS-identified risk SNPs unfortunately only account for a small portion of the 15 
genetic risk for BPD, which suggests there should be additional loci contributing to 16 
the genetic susceptibility. Previous aggregated analyses indicated there may be valid 17 
risk loci underlying genetic markers passing only nominal significance in the 18 
GWASs,9 a possibility confirmed by several later studies. For example, a number of 19 
schizophrenia (SCZ) and BPD susceptibility SNPs did not reach genome-wide 20 
significance in initial GWAS samples, but showed consistent replications in 21 
subsequent independent samples, thus implying that these loci might reflect weak but 22 
true risk signals.10 23 
Genetic loci associated with clinical diagnosis also are expected to be related to 24 
so-called intermediate phenotypes implicated in the biology of genetic risk for BP 25 
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disorder. Previous studies have reported hippocampal dysfunction (e.g., memory 1 
impairment) in BPD patients and their unaffected relatives, implying that variation in 2 
hippocampal biology is an intermediate phenotype related to the genetic risk of 3 
BPD.11 In addition, smaller hippocampal volume has been reported in BPD 4 
patients.12,13 Meanwhile, functional neuroimaging studies have revealed that 5 
dysfunctions of hippocampus and its closely related regions underpin abnormal 6 
affective responses and dysfunctional emotion regulation in BPD.14 Finally, 7 
postmortem studies further support the hypothesis that hippocampal abnormalities are 8 
relevant to the altered synaptic plasticity and diminished resilience in BPD.15 9 
Therefore, analysis of the BPD-associated SNPs on these hippocampus-related 10 
phenotypes may provide a plausible way to uncover their functions in 11 
neurodevelopment, and possibly, their involvements in disease susceptibility. 12 
Recent successes in integrating disease GWAS and gene expression data for 13 
several other complex diseases have been promising,16-18 and we wondered if such an 14 
approach may yield novel results for BPD. Predictably, several lines of evidence have 15 
suggested an enrichment of expression quantitative trait loci (eQTL) among BPD 16 
susceptibility SNPs in the brain,19 further highlighting the importance of integrating 17 
functional annotation of genetic variants for gene expression to advance our 18 
understanding of the biological bases of BPD. In light of these findings, we integrated 19 
a BPD GWAS data from 16,731 individuals and a genome-wide eQTL data from 193 20 
normal human brains, followed by a set of independent replications on both eQTL and 21 
disease associations.  22 
 23 
METHOD  24 
Discovery brain eQTL and BPD GWAS datasets 25 
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The brain eQTL dataset used in this study was reported previously.20 In brief, 1 
after excluding ethnic outliers and samples that were possibly related, a total of 193 2 
independent healthy old (age>65) human cortex samples of European origin were 3 
included in the eQTL analysis. Detailed information about genotyping and expression 4 
profiling as well as statistical methods can be found in the Supplemental Material or 5 
the original publication.20 6 
For the BPD GWAS data, the Psychiatric Genomics Consortium (PGC) BPD 7 
working group recently conducted a meta-analysis of large-scale genome-wide data 8 
on BPD among populations of European descent (PGC1 GWAS).6 In this prior study, 9 
they opted to compare BPD patients that had experienced pathologically relevant 10 
episodes of elevated mood (mania or hypomania) and control subjects from the same 11 
geographic and ethnic populations. In sum, we utilized 2,117,872 SNPs across the 12 
genome from the GWAS samples (7,481 cases and 9,250 controls), and the 13 
association significance (P-value) for these SNPs were downloaded from the PGC1 14 
data sharing website (https://pgc.unc.edu/Sharing.php#SharingOpp). Detailed 15 
descriptions of the samples, data quality, genotype imputation, genomic controls and 16 
statistical analyses can be found in the original GWAS report.6 17 
 18 
Integrative analysis of eQTL and BPD GWAS data 19 
We integrated the eQTL and BPD GWAS data using a Bayesian statistical 20 
framework. Statistical analyses for the eQTL and BPD GWAS was achieved by using 21 
the program Sherlock (http://sherlock.ucsf.edu/), which has been described 22 
elsewhere.17 In brief, Sherlock is based on the rationale that a risk gene for the disease 23 
may have at least one eQTL, and these eQTL could alter gene expression, which in 24 
turn affects disease susceptibility. Given the probability that this is true, there should 25 
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be a significant overlap of the eQTL of a gene and the loci associated with the 1 
disorder, which would imply a likely functional role for the gene in that particular 2 
disease. At this juncture, Sherlock aligns the eQTL and BPD GWASs and only 3 
considers the shared SNPs in both datasets. Sherlock's scoring rubric both increases 4 
the total gene score for overlapping SNPs and provides a penalty in the absence of an 5 
overlap, though associations found only in the BPD GWAS do not alter the score. 6 
Sherlock computes individual Log Bayes Factors (LBFs) for each SNP pair in the 7 
alignment, and the sum of these constitutes the final LBF score for each gene.  8 
 9 
Brain eQTL data for replication analysis  10 
Considering that bipolar disorder is a mental disorder that reasonably originates 11 
from abnormal brain functions, brain samples are presumably appropriate for 12 
replication test of the eQTL results. We first utilized a brain DLPFC (dorsolateral 13 
prefrontal cortex) sample (N=320) consisting of healthy controls in Caucasians and 14 
African Americans (named as “first replication sample”), in which the sample has 15 
been previously used to identify psychiatric risk transcripts.21-23 16 
We also used other well-characterized brain expression databases for replication 17 
analysis of the eQTL associations. A brief description of the gene expression 18 
resources is provided below; more detailed information can be found in the original 19 
studies.18,24-26 (1) BrainCloud: BrainCloud contains genetic information and whole 20 
transcriptome expression data from postmortem DLPFC of 261 normal human 21 
subjects in Caucasians and African Americans. The data in BrainCloud is aimed at 22 
exploring temporal dynamics and genetic control of transcription across lifespan.24 Of 23 
note, there is partial overlap between BrainCloud data and our “first replication 24 
sample”. (2) Data from Webster et al: This report studied whole-genome 25 
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transcriptome and genome in a series of neuropathologically normal postmortem 1 
samples and a confirmed pathologic diagnosis of late-onset Alzheimer disease (LOAD; 2 
final N=188 controls, 176 cases), and suggested that studying the transcriptome as a 3 
quantitative endophenotype has greater power for discovering risk SNPs influencing 4 
expression than the use of discrete diagnostic categories such as presence or absence 5 
of disease.25 It should be noted that the control sample in this study was the same as 6 
our discovery brain eQTL sample.20 (3) SNPExpress: The authors analyzed 7 
genome-wide SNPs that were associated with gene expression in human primary cells 8 
at the exon level, using Affymetrix exon arrays, evaluating 93 autopsy-collected 9 
cortical brain tissue samples with no defined neuropsychiatric condition.26 (4) Data 10 
from Zou et al: They measured expression levels of 24,526 transcripts in brain 11 
samples from the cerebellum and temporal cortex of autopsied subjects with 12 
Alzheimer’s disease (AD, cerebellar n = 197, temporal cortex n = 202), and conducted 13 
a genome-wide expression association study (eGWAS) using 213,528 cis-SNPs within 14 
6,100 kb of the tested transcripts.18 Their results demonstrated the significant 15 
contributions of genetic factors to human brain gene expression, which are reliably 16 
detected across different brain regions, and also implicated that combined assessment 17 
of expression and disease GWAS may provide complementary information in 18 
discovery of human disease variants with functional implications.18 19 
 20 
BPD samples for replication analysis 21 
Replication analyses on BPD were conducted in two steps (replication-I and II), 22 
examining a total of 6,056 BPD cases and 46,614 controls from ten different 23 
geographic locations. Detailed information on each sample—including diagnostic 24 
assessment, genotyping method and quality control—are shown in the Supplemental 25 
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Data and Table S1.  1 
Briefly, the BPD samples used in our replication included: (1) Germany II (181 2 
cases and 527 controls);5 (2) Germany III (490 cases and 880 controls);5 (3) Australia 3 
(330 cases and 1,811 controls);5 (4) France (451 cases and 1,631 controls);2 (5) 4 
Sweden I (836 cases and 2,093 controls);6 (6) Sweden II sample (1,415 cases and 5 
1,271 controls);6 and (7) Iceland (541 cases and 34,546 controls);6 (8) Romania (244 6 
cases and 174 controls),5 and (9) China (350 cases and 888 controls).27 For 7 
replication-II, we used a United Kingdom sample (1,218 cases and 2,913 controls).28 8 
The ten samples from replication-I and II showed no overlap with the PGC1 BPD 9 
samples.6 Each of the original studies was conducted under appropriate ethical 10 
approvals, and written informed consents were obtained from all subjects. 11 
 12 
Samples for analysis of hippocampal volume and cognitive performance 13 
For analysis of hippocampal volume, we utilized the data from a recent GWAS 14 
conducted by the Enhancing Neuro Imaging Genetics through Meta-Analysis 15 
(ENIGMA) consortium.29 The GWAS includes a total of 5,775 young healthy 16 
individuals (mean age: 34.8 years). Detailed information on the samples, imaging 17 
procedures, genotyping methods and statistical analysis can be found in the original 18 
GWAS report.29 19 
For analysis of cognitive performance, we used a Chinese sample that included 20 
342 healthy Chinese college students from Beijing Normal University who had 21 
self-reported no known history of any neurological or psychiatric disorders (197 22 
females and 145 males, aged 18-23). Cognitive and behavioral measures included 23 
working memory, executive functions (as assessed with the Attention Network Test, 24 
the Wisconsin Card Sorting Task, and a reversal learning test), and motivation traits 25 
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etc., which were shown in Table S2. This experiment was approved by the 1 
Institutional Review Board of the State Key Laboratory of Cognitive Neuroscience 2 
and Learning at Beijing Normal University, China. Written informed consent was 3 
obtained from all participants following a full explanation of the study procedure. 4 
 5 
Statistical analysis 6 
For the replication analysis on BPD, genomic control was used to correct for 7 
relatedness and population stratification in each sample,30 and association P-values 8 
and allele-specific odds ratios (ORs) for each individual sample were calculated by a 9 
logistic regression model with an additive effect using a lambda value (genomic 10 
control) as a covariate to adjust for potential population stratification. Meta-analyses 11 
were then conducted based on Z-scores by combining data from different samples in 12 
the R package (meta module) using the Mantel-Haenszel method under the fixed 13 
effects model. As described in previous GWAS meta-analysis,6 P-values for 14 
replication samples are reported as one-tailed tests, while P-values for all combined 15 
samples are shown as two-tailed tests. We used a forest plot to graphically present the 16 
individual OR and their 95% confidence interval, i.e., each sample was represented by 17 
a square in the forest plot. For the analyses on cognitive performance, two-tailed 18 
t-tests were conducted with SPSS 16.0 (SPSS, Chicago, USA).  19 
To explain the logic of the study design, a flow chart about the analytical methods 20 
and how variants were taken forward from one stage of analysis to the next was 21 
shown in Figure 1. All protocols and methods used in this study were approved by the 22 
institutional review board of Kunming Institute of Zoology, Chinese Academy of 23 
Sciences and adhere to all relevant national and international regulations. 24 
 25 
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 1 
RESULTS 2 
Integrative analysis of eQTL and BPD GWAS data 3 
The Sherlock identified a total 20,942 SNPs showing significant eQTL effects, 4 
and also having BPD data (e.g., p-value), and these SNPs were included for further 5 
analyses. Using a Bayesian statistical method to match the “signature” of genes from 6 
the brain eQTL with patterns of association in the BPD GWAS, we ranked the top 7 
candidate genes for BPD risk according to their LBF scores and P-values. Only genes 8 
with LBF scores higher than 5.00 were shown and included for further analyses. 9 
The integrative analysis yielded four candidate risk genes (Table S3). The first 10 
gene was glycosyltransferase 8 domain containing 1 (GLT8D1, LBF=6.78), located 11 
on chromosome 3p21.1 that has been repeatedly reported for association with 12 
BPD.31,32 Detailed analysis found that the significant association with this gene was 13 
mainly driven by a cis-associated SNP rs2251219. This SNP has already been 14 
reported in an earlier GWAS of BPD,32 and was replicated in independent BPD 15 
samples (in which their samples overlapped with our replication samples).33-35 The 16 
second top-ranked gene was chemokine (C-X-C motif) ligand 16 (CXCL16, 17 
LBF=6.16) on chromosome 17p13. To the best of our knowledge, this gene has never 18 
been reported in genetic association studies on BPD, and we observed two trans- 19 
associated SNPs showing moderate associations with BPD. The third top-ranked gene 20 
was TRPC4AP (LBF=5.57) on chromosome 20q11.22, with the significance mainly 21 
driven by a cis-associated SNP (rs6088662, p-val=5.85×10-5 with BPD). The last 22 
top-ranked gene was TAF11 (TAF11 RNA polymerase II, TATA box binding 23 
protein-associated factor, 28kDa) on chromosome 6p21.31, with a trans-correlated 24 
SNP (rs4482754) showed significant association with BPD. 25 
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 1 
Replication of eQTL effects in diverse samples 2 
Given the myriad confounders in single eQTL database, it is important and 3 
necessary to validate the eQTL associations in independent samples. The above four 4 
candidate genes and their cis- or trans- associated SNPs were followed-up in 5 
independent eQTL datasets. 6 
For the cis-SNP rs2251219 and GLT8D1, we observed significant association in 7 
one replication sample of AD source (Table S4),25 and a marginal significant 8 
association in the BrainCloud sample.24 However, as demonstrated by a previous 9 
study,32 the association of rs2251219 with GLT8D1 expression in our discovery eQTL 10 
sample (Myers et al. study)20 may be an artifact since the probes overlapped with 11 
other common SNPs, and it could not be replicated in the original cDNA samples of 12 
our discovery eQTL dataset by quantitative PCR using the probes not overlapping 13 
with known SNPs. In addition to GLT8D1, we also analyzed the expression of other 14 
nearby genes around rs2251219, however, no promising findings were observed 15 
(Table S4). For the significant trans- eQTL associations in our discovery sample, 16 
neither CXCL16 nor TAF11 could be validated in any of the replication samples 17 
(Table S5), implying they might be generated by chance. 18 
For the cis-association between rs6088662 and TRPC4AP expression, in the 19 
discovery eQTL brain sample,20 the risk allele [G] of rs6088662 showed significantly 20 
decreased gene expression (p<1.0×10-8, Figure 2A). This pattern was validated in one 21 
of the replication samples (p<1.0×10-8 in Webster et al. study),25 but it should be noted 22 
that this replication data includes our discovery sample. We therefore re-analyzed the 23 
result using the non-overlapped AD patients, and it showed nominally significant 24 
association (p=0.023, Figure 2B). However, rs6088662 showed an opposite effect on 25 
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TRPC4AP expression in our “first replication sample” (risk allele [G] of rs6088662 1 
showed increased gene expression), and in other replication samples, no significant 2 
association between rs6088662 and TRPC4AP was observed (Table S6).18,26 These 3 
inconsistencies may not be surprising, given a prior report of low-to-moderate overlap 4 
between eQTL loci across eQTL studies (the percentage of overlapped eQTL is 5 
0~35.4% between pairwise brain studies, shown in Table 4 of McKenzie et al. 6 
study).36 In addition, with the use of several non-brain tissue eQTL databases,37-39 we 7 
also observed significant and consistent associations between rs6088662 and 8 
TRPC4AP expression (the p-values range from 0.047 to 3.60×10-7, Figure S1-S3). 9 
To further dissect if rs6088662 is also associated with the expression of other 10 
nearby genes, we screened 14 genes in the 20q11.22 region in both discovery and 11 
replication eQTL samples (Table S6). Intriguingly, we observed another gene GGT7 12 
showing significant association in the discovery sample (p<1.0×10-7, Figure 3A), and 13 
it remained significant in the “first replication sample” with the same direction of 14 
effect (p<1.0×10-8, Figure 3B). In other replication samples, the association is also 15 
significant (Webster et al.25 and Zou et al.18 studies, Figure 3C and Table S6) or 16 
marginal significant (BrainCloud24), except for Heinzen et al. study (p=0.13),26 17 
however, in the Heinzen et al. sample, rs6088662 still showed one of the strongest 18 
associations with GGT7 among the genes in 20q11.22, and the SNP showed 19 
significant or marginal significant associations with the expression of several exons in 20 
GGT7 (Table S7), which was not observed in most of other nearby genes. 21 
For the other genes in 20q11.22, three of them (ACSS2, MYH7B and EDEM2) 22 
also showed associations in some of the eQTL samples, but the associations are not 23 
consistent, and these genes are unlikely the associated genes (Table S6). To 24 
summarize, from the eQTL analyses in both discovery and replication samples, we 25 
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demonstrated that rs6088662 is likely an authentic eQTL SNP, and we found two 1 
potential genes (GGT7 and TRPC4AP) showing association with this risk SNP.  2 
 3 
Rs6088662 is associated with bipolar disorder across cohorts 4 
Given the replication of significant associations between rs6088662 and 5 
TRPC4AP expression, we opted to pursue further analysis of this SNP on BPD risk. In 6 
the stage I replication analysis, rs6088662 was analyzed in nine independent 7 
case-control samples. Although the association between rs6088662 and BPD did not 8 
achieve even nominal significance (p=0.05) in any single cohort, it does show a trend 9 
of association in Germany II and Sweden II samples (p=0.08 and p=0.07, 10 
respectively). In a Chinese sample, there is no difference in allele frequencies of this 11 
SNP between Han Chinese and Europeans (0.165 versus 0.171 for G allele), and the 12 
effect size (OR) in the Chinese sample was even higher than in our discovery sample 13 
(1.17 versus 1.12), the non-significant result being likely due to the limited sample 14 
size. When all the replication-I samples were combined, the association p-value 15 
reached nominal significance level (p=4.95×10-2), with the OR being 1.06 (95% 16 
CI=0.99-1.13), consistent with the discovery PGC1 GWAS. There is no significant 17 
heterogeneity among the replication-I samples (p=0.77), and detailed results for each 18 
individual sample were shown in Table 1. The forest plot of the meta-analysis on all 19 
replication-I samples is presented in Figure 4. 20 
Notably, a previous study28 has reported a significant association of a proxy SNP 21 
of rs6088662 (rs13041792, r2=1.00 with rs6088662 in Europeans) with BPD in an 22 
independent UK sample (1,218 cases and 2,913 controls), which is in concordant with 23 
our results and was also included in our analysis, denoted as “replication-II” sample. 24 
Meta-analysis by combining PGC1 GWAS, replication-I and replication-II samples 25 
14 
 
yielded a genome-wide significant association of rs6088662 with BPD (p=3.54×10-8, 1 
OR=1.12, 95% CI=1.07-1.16, Table 1). We used the fixed effect model for 2 
meta-analysis because there was no significant heterogeneity among the samples 3 
(p>0.05).  4 
Considering the genetic overlap between BPD and other psychiatric disorders 1, 5 
we also tested the association of rs6088662 with two other mental disorders, SCZ and 6 
major depressive disorder (MDD). It showed nominally significant association with 7 
SCZ in the latest PGC2 GWAS (p=0.0037, OR=1.04, 95% CI=1.00-1.08, 8 
N=35,476/46,839),40 however, it did not show any significant associations with MDD 9 
when using data from the PGC1 MDD GWAS plus Colaus study samples 10 
(10,541/11,208) (Table S8),41,42 implying that rs6088662 is likely a psychosis risk 11 
SNP rather than a risk SNP for a broader spectrum of mood disorders.  12 
A proxy search for SNPs in high LD with rs6088662 was performed on the SNAP 13 
website (http://www.broadinstitute.org/mpg/snap/ldsearch.php) with the European 14 
panel from the 1000 Genomes Project (pilot 1) dataset. This identified 43 SNPs in 15 
high LD (r2>0.8) with rs6088662, all of which are located within MYH7B and 16 
TRPC4AP regions (Figure 5). Among these, there are 1 non-synonymous SNP, 3 17 
synonymous SNPs, 1 SNP in the 5’ untranslated region (UTR), and 1 SNP located in 18 
the non-coding RNA (ncRNA) region (Table S9). However, to identify causal 19 
variants for BPD, further studies are needed. 20 
 21 
Rs6088662 is associated with hippocampal volume and cognitive performance 22 
To move beyond statistical association with clinical diagnosis and to obtain 23 
convergent evidence for association between rs6088662 and BPD-related biology, we 24 
also performed a series of convergent experiments testing risk-associated SNPs on 25 
15 
 
several intermediate biological phenotypes. The hippocampus is a subcortical brain 1 
region frequently reported to show dysfunction among BPD patients.18,23 We therefore 2 
hypothesized that if the identified risk-associated SNP (e.g., rs6088662) affects the 3 
anatomy or function of this brain region, then related cognitive deficits, regardless of 4 
illness status should be associated with it. In an exploratory manner, we tested the 5 
effects of rs6088662 on the biological phenotypes related to the hippocampus 6 
(hippocampal volume and cognitive performance) in healthy subjects.  7 
In the ENIGMA sample, rs6088662 was significantly associated with 8 
hippocampal volume across multiple cohorts (p=0.00063, β=27.29 mm3, Table S10), 9 
supporting the prior speculation that the BPD-associated SNPs will likely affect 10 
hippocampal structure, but detailed analysis found that the risk allele [G] led to larger 11 
volume. As a post hoc exploratory test, we then investigated the potential impacts of 12 
rs6088662 on cognitive performance, and found that rs6088662 showed nominally 13 
significant association with executive functions (the alert attention task) (p=0.0094, 14 
Table S11) and language abilities (visual-auditory) (p=0.012, Table S11). Again, the 15 
risk allele [G] indicated a better cognitive performance.  16 
Analysis on BPD-related phenotypes further confirmed the role of the risk SNPs 17 
in BPD susceptibility and implied it may be functional in the brain. However, as the 18 
association results on these intermediate phenotypes (especially for cognitive 19 
performance) may not survive multiple correction, further validation in larger samples 20 
are needed. In addition, the discrepancy of allelic directionality between clinical 21 
diagnosis and intermediate phenotypes suggests that the molecular mechanism at 22 
work may be more complicated than what we had initially expected when undertaking 23 
this study.  24 
 25 
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DISCUSSION 1 
Findings relating to 20q11.22 region 2 
In this study, with an integrative analysis on both expression and BPD data, we 3 
identified a potential risk region 20q11.22 for BPD, although it is still unclear which 4 
SNPs are actually responsible. This genomic region contains an extensive area of high 5 
LD spanning ~276 kb, including at least 5 protein coding genes (Figure 5). Of the 43 6 
common SNPs in high LD (r2>0.8) with rs6088662, there is one non-synonymous 7 
SNP, three synonymous SNPs, one SNP in the 5’ UTR area of genes, and one SNP 8 
located in the ncRNA region, all of which are potentially functional but as of yet 9 
unknown roles (Table S9).  10 
We found a nominally significant association of BPD-risk SNPs with 11 
hippocampal volume and cognitive performance, which is consistent with the 12 
prevalent perspective that many BPD-related genes also affect brain structures and 13 
cognitive functions. Rather perplexingly though, the risk allele of rs6088662 actually 14 
seemed to be associated with larger hippocampal volume and better cognition, 15 
running entirely opposite to the conventional view that risk alleles generally lead to 16 
smaller hippocampal volume and worse cognition. One potential speculative 17 
explanation is that the risk genes (GGT7 and/or TRPC4AP) may play diverse roles in 18 
neural development, and the SNP has pleiotropic effects--some detrimental and some 19 
beneficial. Another possible explanation is that gene-behavior association differs by 20 
diagnosis status, as previous studies also reported other similar situations: for example, 21 
the psychosis risk allele of rs1344706 in ZNF804A is associated with better cognitive 22 
performance in SCZ patients seen in two independent samples.43,44 Likewise, another 23 
psychosis risk SNP (rs1006737) in CACNA1C was shown to be associated with larger 24 
gray matter volume for those with the risk allele.45,46  25 
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 1 
Additional evidence of GGT7 and TRPC4AP in bipolar disorder 2 
TRPC4AP is known to be a substrate-specific adapter of a DCX 3 
(DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle 4 
control, and GGT7 is a member of a gene family that encodes enzymes involved in 5 
metabolism of glutathione and in the transpeptidation of amino acids, however, their 6 
roles in susceptibility to BPD are still unclear. Here we studied the spatial expression 7 
profiling of GGT7 and TRPC4AP in multiple human tissues to see if they are enriched 8 
in brain tissues, as BPD is a mental disorder that mainly originates from abnormal 9 
brain function, and if these genes are preferentially expressed in brain, which would 10 
make more sense of taking them as potential risk genes for BPD. We used the 11 
expression data from Genotype-Tissue Expression project (GTEx),47 in which 3,797 12 
tissues from 150 post-mortem donors have been collected and subsequently analyzed 13 
using a RNA sequencing (RNA-seq) based gene expression approach. Notably, we 14 
found GGT7 is abundantly expressed in human brain tissues, such as cerebellum 15 
(Figure S4-A), while the expression level of GGT7 is generally low in non-neural 16 
tissues. However, the expression of TRPC4AP in brains is relatively lower than other 17 
tissues (Figure S4-B), but this gene has been previously reported in association with 18 
Alzheimer’s disease (AD),48,49 a neurological disorder showing a high comorbidity 19 
with affective disorders (such as BPD and MDD) in geriatric populations.50 20 
 21 
Implications 22 
Alongside our specific findings for genetic susceptibility to BPD, our results 23 
highlight several advantages of convergent analysis using BPD and eQTL GWAS 24 
datasets (Figure 1) over conventional analytical strategies aimed at uncovering 25 
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susceptibility genes. First, analyses such as ours may identify genes that may be 1 
missed by traditional univariate analytical approaches, because these genes tend to be 2 
authentic risk genes but with small effects. Second, the identification of eQTL effects 3 
of the risk SNPs could provide insights for future focused studies, since conventional 4 
analyses often observed a large LD region containing numerous genes showing 5 
association with the illness, but actually determining which one is the susceptibility 6 
gene is difficult at best. Third, significant association between eQTL and illness has 7 
been consistently replicated across independent datasets, providing convergent 8 
validity for findings and suggesting potentially higher reproducibility for this kind of 9 
system-level analysis. Given these advantages, it is likely that further studies using 10 
similar methods will strengthen the case for such studies in trying to uncover genetic 11 
risk factors for psychiatric diseases. 12 
 13 
Study limitations 14 
While this study offers some interesting observations, it should be noted that the 15 
present evidence is limited, and we are cautious in interpreting these results. (1) In the 16 
integrative analysis on BPD and eQTL GWAS data, we arbitrarily selected genes that 17 
were scored higher than 5.0 (LBF scores). As such, it is possible that some genes that 18 
may contribute to BPD risk but did not meet our selection criteria could have been 19 
missed. (2) Similarly, while we used GWAS data in our analysis, the SNP coverage is 20 
still relatively low and other true risk SNPs may have been missed. Due to the dearth 21 
of functional data, it is difficult to identify the causative variant(s). (3) Likewise, we 22 
cannot exclude the possibility that the positive association signal was actually caused 23 
by the hitch-hiking effect of rare missense mutations, copy number variations or 24 
variants in a distant region. Further focused studies may provide a more complete 25 
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survey. (4) The SNPs in the discovery eQTL sample were not imputed, thus reducing 1 
the overlap between eQTL and GWAS data sets and the power of our method, 2 
although we believe the obtained results are valuable. (5) The gene expression 3 
coverage in the discovery eQTL dataset is relative low, and we cannot exclude the 4 
possibility of other missing risk genes during the integrative analyses, although we 5 
conducted a comprehensive replication and fine-mapping analyses to localize the 6 
actual risk genes. Further studies using a high-coverage array or RNA-sequencing are 7 
warranted. (6) It also should be acknowledged that the eQTL databases that we used 8 
are highly variable, in terms of expression platforms and tissue quality, age, and 9 
diagnoses. It is highly likely that biological factors mediating eQTL associations, such 10 
as epigenetic regulation, transcription factor binding, and microRNA dynamics will 11 
vary across age and diagnosis. (7) We also would note that our results reached 12 
genome wide significance in the final meta-analysis of our ten new samples added to 13 
the public BPD dataset. Our understanding of the association of rs6088662 with BPD 14 
and with gene expression and hippocampal biology might have started first with the 15 
combined GWAS result, but this was not our strategy.  16 
 17 
Conclusions 18 
In conclusion, our data from large-scale samples support that SNPs in a region on 19 
chromosome 20q11.22 are significantly associated with BPD. We observed 20 
associations with GGT7 and TRPC4AP mRNA expression, hippocampal volume and 21 
cognitive performance. Although the actual risk gene(s) for BPD in this genomic 22 
region are yet to be determined, future studies may give a more compelling picture on 23 
the association between these potential risk factors and genetic susceptibility to BPD. 24 
25 
20 
 
Supplemental Data  1 
Supplementary material cited in this article is available online. 2 
 3 
Funding 4 
This work was supported by grants from the National 973 project of China 5 
(2011CBA00401), the National Natural Science Foundation of China (U1202225, 6 
31130051, 31071101 and 31221003), the German Federal Ministry of Education and 7 
Research (BMBF), the National Genome Research Network (NGFN), the Integrated 8 
Genome Research Network (IG) MooDS (grant 01GS08144 to SC and MMR, grant 9 
01GS08147 to MR and TGS), 111 Project (B07008) of the Ministry of Education of 10 
China, the Strategic Priority Research Program (B) of the Chinese Academy of 11 
Sciences (XDB02020000), the National Authority for Scientific Research, Bucharest, 12 
Romania (UEFISCDI - PN-II-89/2012) and Personal Genetics SRL, Bucharest, 13 
Romania. 14 
 15 
Acknowledgements 16 
We would like to acknowledge the efforts of the Bipolar Disorder Working Group of 17 
Psychiatric GWAS Consortium in their contribution to this study. We are deeply 18 
grateful for Stacy Steinberg, Hreinn Stefansson, Kari Stefansson, Thorgeir 19 
Thorgeirsson (deCODE genetics, Reykjavik, Iceland) and Engilbert Sigurdsson 20 
(Landspitali University Hospital, Reykjavík, Iceland) for their results in Iceland 21 
samples. We are also grateful to Andrew Willden (Kunming Institute of Zoology) for 22 
language editing of the manuscript. 23 
24 
21 
 
References 1 
1 Craddock N, Jones I. Genetics of bipolar disorder. J Med Genet. 1999; 36: 585-94. 2 
2 Etain B, Dumaine A, Mathieu F, Chevalier F, Henry C, Kahn JP, et al. A SNAP25 promoter 3 
variant is associated with early-onset bipolar disorder and a high expression level in brain. Mol 4 
Psychiatry. 2009; 15: 748-55. 5 
3 Li M, Luo XJ, Rietschel M, Lewis CM, Mattheisen M, Muller-Myhsok B, et al. Allelic 6 
differences between Europeans and Chinese for CREB1 SNPs and their implications in gene 7 
expression regulation, hippocampal structure and function, and bipolar disorder susceptibility. Mol 8 
Psychiatry. 2014; 19: 452-61. 9 
4 Chen DT, Jiang X, Akula N, Shugart YY, Wendland JR, Steele CJ, et al. Genome-wide association 10 
study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with 11 
bipolar disorder. Mol Psychiatry. 2011; 18: 195-205. 12 
5 Cichon S, Muhleisen TW, Degenhardt FA, Mattheisen M, Miro X, Strohmaier J, et al. 13 
Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for 14 
bipolar disorder. Am J Hum Genet. 2011; 88: 372-81. 15 
6 Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N, et al. Large-scale 16 
genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. 17 
Nat Genet. 2011; 43: 977. 18 
7 Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, et al. Collaborative 19 
genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat 20 
Genet. 2008; 40: 1056-8. 21 
8 Muhleisen TW, Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J, et al. 22 
Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun. 2014; 5: 23 
3339. 24 
9 Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common 25 
polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009; 460: 26 
748-52. 27 
10 Steinberg S, de Jong S, Andreassen OA, Werge T, Borglum AD, Mors O, et al. Common variants 28 
at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet. 2011; 20: 4076-81. 29 
11 Quraishi S, Walshe M, McDonald C, Schulze K, Kravariti E, Bramon E, et al. Memory 30 
functioning in familial bipolar I disorder patients and their relatives. Bipolar Disord. 2009; 11: 209-14. 31 
12 Rimol LM, Hartberg CB, Nesvag R, Fennema-Notestine C, Hagler DJ, Jr., Pung CJ, et al. Cortical 32 
thickness and subcortical volumes in schizophrenia and bipolar disorder. Biol Psychiatry. 2010; 68: 33 
41-50. 34 
13 Haukvik UKW, L. T.; Mørch-Johnsen, L.; Jørgensen, K. N.; Lange, E. H.; Dale, A. M.; Melle, I.; 35 
Andreassen, O. A.; Agartz, I. In vivo hippocampal subfield volumes in schizophrenia and bipolar 36 
disorder. Biol Psychiatry. 2014; DOI: 10.1016/j.biopsych.2014.06.020. 37 
14 Phillips ML, Ladouceur CD, Drevets WC. A neural model of voluntary and automatic emotion 38 
regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar 39 
disorder. Mol Psychiatry. 2008; 13: 829, 33-57. 40 
15 Frey BN, Andreazza AC, Nery FG, Martins MR, Quevedo J, Soares JC, et al. The role of 41 
hippocampus in the pathophysiology of bipolar disorder. Behav Pharmacol. 2007; 18: 419-30. 42 
16 Conde L, Bracci PM, Richardson R, Montgomery SB, Skibola CF. Integrating GWAS and 43 
expression data for functional characterization of disease-associated SNPs: an application to follicular 44 
22 
 
lymphoma. Am J Hum Genet. 2013; 92: 126-30. 1 
17 He X, Fuller CK, Song Y, Meng Q, Zhang B, Yang X, et al. Sherlock: detecting gene-disease 2 
associations by matching patterns of expression QTL and GWAS. Am J Hum Genet. 2013; 92: 667-80. 3 
18 Zou F, Chai HS, Younkin CS, Allen M, Crook J, Pankratz VS, et al. Brain expression 4 
genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet. 5 
2012; 8: e1002707. 6 
19 Gamazon ER, Badner JA, Cheng L, Zhang C, Zhang D, Cox NJ, et al. Enrichment of 7 
cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder 8 
susceptibility variants. Mol Psychiatry. 2012; 18: 340-6. 9 
20 Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, Marlowe L, et al. A survey of genetic human 10 
cortical gene expression. Nat Genet. 2007; 39: 1494-9. 11 
21 Morita Y, Callicott JH, Testa LR, Mighdoll MI, Dickinson D, Chen Q, et al. Characteristics of the 12 
cation cotransporter NKCC1 in human brain: alternate transcripts, expression in development, and 13 
potential relationships to brain function and schizophrenia. J Neurosci. 2014; 34: 4929-40. 14 
22 Nakata K, Lipska BK, Hyde TM, Ye T, Newburn EN, Morita Y, et al. DISC1 splice variants are 15 
upregulated in schizophrenia and associated with risk polymorphisms. Proc Natl Acad Sci U S A. 2009; 16 
106: 15873-8. 17 
23 Tao R, Li C, Newburn EN, Ye T, Lipska BK, Herman MM, et al. Transcript-specific associations 18 
of SLC12A5 (KCC2) in human prefrontal cortex with development, schizophrenia, and affective 19 
disorders. J Neurosci. 2012; 32: 5216-22. 20 
24 Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT, et al. Temporal dynamics and genetic 21 
control of transcription in the human prefrontal cortex. Nature. 2011; 478: 519-23. 22 
25 Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P, et al. Genetic control of human 23 
brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009; 84: 445-58. 24 
26 Heinzen EL, Ge D, Cronin KD, Maia JM, Shianna KV, Gabriel WN, et al. Tissue-specific genetic 25 
control of splicing: implications for the study of complex traits. PLoS Biol. 2008; 6: e1. 26 
27 Zhang X, Zhang C, Wu Z, Wang Z, Peng D, Chen J, et al. Association of genetic variation in 27 
CACNA1C with bipolar disorder in Han Chinese. J Affect Disord. 2013; 150: 261-5. 28 
28 Green EK, Hamshere M, Forty L, Gordon-Smith K, Fraser C, Russell E, et al. Replication of 29 
bipolar disorder susceptibility alleles and identification of two novel genome-wide significant 30 
associations in a new bipolar disorder case-control sample. Mol Psychiatry. 2013; 18: 1302-7. 31 
29 Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, et al. Identification of 32 
common variants associated with human hippocampal and intracranial volumes. Nat Genet. 2012; 44: 33 
552-61. 34 
30 Devlin B, Roeder K. Genomic control for association studies. Biometrics. 1999; 55: 997-1004. 35 
31 Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, Upmanyu R, et al. Genome-wide 36 
association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad 37 
Sci U S A. 2009; 106: 7501-6. 38 
32 McMahon FJ, Akula N, Schulze TG, Muglia P, Tozzi F, Detera-Wadleigh SD, et al. Meta-analysis 39 
of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet. 40 
2010; 42: 128-31. 41 
33 Breen G, Lewis CM, Vassos E, Pergadia ML, Blackwood DH, Boomsma DI, et al. Replication of 42 
association of 3p21.1 with susceptibility to bipolar disorder but not major depression. Nat Genet. 2011; 43 
43: 3-5; author reply  44 
23 
 
34 Kondo K, Ikeda M, Kajio Y, Saito T, Iwayama Y, Aleksic B, et al. Genetic variants on 3q21 and in 1 
the Sp8 transcription factor gene (SP8) as susceptibility loci for psychotic disorders: a genetic 2 
association study. PLoS One. 2013; 8: e70964. 3 
35 Vassos E, Steinberg S, Cichon S, Breen G, Sigurdsson E, Andreassen OA, et al. Replication study 4 
and meta-analysis in European samples supports association of the 3p21.1 locus with bipolar disorder. 5 
Biol Psychiatry. 2012; 72: 645-50. 6 
36 McKenzie M, Henders AK, Caracella A, Wray NR, Powell JE. Overlap of expression quantitative 7 
trait loci (eQTL) in human brain and blood. BMC Med Genomics. 2014; 7: 31. 8 
37 Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, Attar-Cohen H, et al. Common 9 
regulatory variation impacts gene expression in a cell type-dependent manner. Science. 2009; 325: 10 
1246-50. 11 
38 Nica AC, Parts L, Glass D, Nisbet J, Barrett A, Sekowska M, et al. The architecture of gene 12 
regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet. 2011; 7: 13 
e1002003. 14 
39 Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE, et al. Patterns of cis 15 
regulatory variation in diverse human populations. PLoS Genet. 2012; 8: e1002639. 16 
40 Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 17 
schizophrenia-associated genetic loci. Nature. 2014; 511: 421-7. 18 
41 Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, Breen G, et al. A mega-analysis of 19 
genome-wide association studies for major depressive disorder. Mol Psychiatry. 2012; 18: 497-511. 20 
42 Preisig M, Waeber G, Vollenweider P, Bovet P, Rothen S, Vandeleur C, et al. The PsyCoLaus 21 
study: methodology and characteristics of the sample of a population-based survey on psychiatric 22 
disorders and their association with genetic and cardiovascular risk factors. BMC Psychiatry. 2009; 9: 23 
9. 24 
43 Walters JT, Corvin A, Owen MJ, Williams H, Dragovic M, Quinn EM, et al. Psychosis 25 
susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry. 2010; 26 
67: 692-700. 27 
44 Chen M, Xu Z, Zhai J, Bao X, Zhang Q, Gu H, et al. Evidence of IQ-modulated association 28 
between ZNF804A gene polymorphism and cognitive function in schizophrenia patients. 29 
Neuropsychopharmacology. 2012; 37: 1572-8. 30 
45 Wang F, McIntosh AM, He Y, Gelernter J, Blumberg HP. The association of genetic variation in 31 
CACNA1C with structure and function of a frontotemporal system. Bipolar Disord. 2011; 13: 696-700. 32 
46 Perrier E, Pompei F, Ruberto G, Vassos E, Collier D, Frangou S. Initial evidence for the role of 33 
CACNA1C on subcortical brain morphology in patients with bipolar disorder. Eur Psychiatry. 2011; 34 
26: 135-7. 35 
47 Consortium GT. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013; 45: 580-5. 36 
48 Poduslo SE, Huang R, Huang J. The frequency of the TRPC4AP haplotype in Alzheimer's 37 
patients. Neurosci Lett. 2009; 450: 344-6. 38 
49 Poduslo SE, Huang R, Huang J, Smith S. Genome screen of late-onset Alzheimer's extended 39 
pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet. 2009; 40 
150B: 50-5. 41 
50 Teipel SJ, Walter M, Likitjaroen Y, Schonknecht P, Gruber O. Diffusion tensor imaging in 42 
Alzheimer's disease and affective disorders. Eur Arch Psychiatry Clin Neurosci. 2014. 43 
 44 
45 24 
 
Table 1. Summary of logistic regression results for rs6088662 across cohorts. 1 
Sample Ethnicity Cases Controls Effect Allele 
Additive 
P-value 
Odds 
ratio 95% CI Data source 
Discovery         
PGC1 Europeans 7,481 9,250 G 5.85×10-5 1.12 1.06-1.19 6 
         
Replication-I         
Germany II German 181 527 G 0.08 1.23 0.91-1.65 this study 
Germany III German 490 880 G 0.16 1.09 0.90-1.33 this study 
Australia Australian 330 1,811 G 0.29 1.07 0.85-1.33 this study 
France French 451 1,631 G 0.42 1.02 0.85-1.22 this study 
Sweden I Swedish 836 2,093 G 0.37 1.02 0.89-1.18 this study 
Sweden II Swedish 1,415 1,271 G 0.07 1.12 0.97-1.29 this study 
Iceland Icelandic 541 34,426 G 0.19 0.93 0.79-1.10 this study 
Romania Romanian 244 174 G 0.42 1.04 0.74-1.46 this study 
China Han Chinese 350 888 G 0.11 1.17 0.91-1.50 this study 
All replication-I samples  4,838 43,701 G 4.95×10-2 1.06 0.99-1.13  
         
Replication-II         
UK British 1,218 2,913 G 1.06×10-6 1.34 1.19-1.51 28 
         
Discovery + Replications  13,537 55,864 G 3.54×10-8 1.12 1.07-1.16  
 2 
Test of heterogeneity 3 
All replication-I cohorts: p=0.77, I2=0%; meta-analysis was conducted under fixed effect model 4 
Discovery + Replication samples: p=0.07, I2=41.8%; meta-analysis was conducted under fixed effect model 5 
 6 
Abbreviations:  7 
CI, confidence interval. 8 
 9 
Note: 10 
P-values are two-sided for the discovery cohort and combined analysis; one-sided P-values are listed for the 11 
replication-I samples 12 
13 
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FIGURE LEGENDS 1 
 2 
Figure 1. Flow chart of the present study. 3 
Based on the hypothesis that BPD risk variants are enriched among eQTL, we 4 
systematically integrated BPD GWAS and genome-wide brain eQTL data by using 5 
Sherlock. The top genes identified by Sherlock were then replicated in independent 6 
BPD samples and eQTL datasets. Finally, the successfully replicated SNP (rs6088662) 7 
was further tested for the association with BPD biological phenotypes including 8 
hippocampal volume and cognitive performance.  9 
 10 
26 
 
 1 
Figure 2. Rs6088662 is significantly associated with TRPC4AP mRNA expression.  2 
(A) Results in 193 neuropathologically normal human brain (cortical) samples of 3 
European subjects. (B) Results in 176 Alzheimer’s disease human brain (cortical) 4 
samples of European subjects. 5 
 6 
Figure 3. Rs6088662 is significantly associated with GGT7 mRNA expression.  7 
(A) Results in 193 neuropathologically normal human brain (cortical) samples of 8 
27 
 
European subjects. (B) Results in 320 healthy human brain DLPFC samples of 1 
Caucasian and African American individuals. (C) Results in 176 Alzheimer’s disease 2 
human brain (cortical) samples of European subjects. 3 
 4 
Figure 4. Forest plot of odds ratios with 95% confidence interval for total 5 
replication-I bipolar disorder samples included in meta-analysis of rs6088662. 6 
The G allele of rs6088662 is overrepresented in BPD cases in all of the tested cohorts 7 
(except for the Iceland sample).  8 
 9 
Figure 5. Plot of chromosome region showing a genomic area of high linkage 10 
disequilibrium with rs6088662 in European populations. 11 
28 
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Description about discovery eQTL database 
 
The brain eQTL dataset used in this study was reported previously.1 In brief, human 
cortex samples were collected from the National Institute of Aging Alzheimer Centers 
and the Miami Brain Bank and the original subjects met several criteria: (a) 
self-defined as being ethnically of European descent; (b) had no clinical history of 
stroke, cerebrovascular disease, Lewy bodies or co-morbidity with neurological 
disease; (c) were assessed by board certified neurologists who made a determination 
on their condition; and (d) had an age at death greater than 65 years. After excluding 
ethnic outliers and samples that were possibly related, a total of 193 independent 
subjects’ samples remained for subsequent analysis. 
Genotyping of the 193 cortex samples was conducted using Affymetrix GeneChip 
Human Mapping 500K Array Set, and mRNA expression measurements were 
performed using Illumina HumanRefseq-8 Expression BeadChip using standard 
manufacturer’s protocols. The PLINK program was used to carry out as a 
one-degree-of-freedom allelic test of association, and the associations results were 
further separated into cis and trans significantly associated SNP-transcript pair sets. 
Cis SNPs were defined as SNPs within either 1 Mb of the 5’ or 3’ end of the transcript 
and within the transcript. Sherlock considers both cis and trans eQTL SNPs. Detailed 
information about genotyping and expression profiling as well as statistical methods 
can be found in the original publication.1 
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Description about non-brain tissue replication eQTL databases 
 
The non-brain tissue eQTL databases were retrieved through Genevar,2 which have 
ever been reported by Nica et al,3 Dimas et al,4 and Stranger et al5 In brief, Nica et al 
explored in depth the roles of genetic variation on gene expression in three human 
tissues: lymphoblastoid cell lines (LCL), skin, and adipose, and the samples (156 LCL, 
160 skin, 166 adipose) derived simultaneously from a subset of healthy female twins 
of the MuTHER resource;3 Dimas et al conducted the genome-wide expression 
analysis in three types of cells (fibroblast, LCL and T-cell) from 75 Geneva GenCord 
Caucasian individuals;4 Stranger et al analyzed genome-wide gene expression in LCL 
from 8 global populations of the HapMap3 project and correlated gene expression 
levels with HapMap3 SNPs located in cis to the genes. We used the data from the 
Caucasian samples (N=109) reported by Stranger et al5 In these three datasets, all the 
statistical analysis between SNPs and gene expression were conducted using 
Spearman’s correlation. 
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Replication-I sample information (see Table DS1) 
 
Germany II and III sample 
Cases for Germany II and III samples were again ascertained from consecutive 
admissions to the inpatient units of the Department of Psychiatry and Psychotherapy 
at the University of Bonn and at the Central Institute for Mental Health in Mannheim, 
University of Heidelberg, as well as at other collaborating psychiatric university 
hospitals in Germany. DSM-IV lifetime diagnoses of bipolar disorder were assigned 
using a consensus best-estimate procedure, based on all available information, 
including structured interviews (SCID-I, SADS-L; Germany III) or semi-structured 
interviews (AMDP; Germany II), medical records, and the family history method. In 
addition, the OPCRIT system was used for the detailed polydiagnostic documentation 
of symptoms.6 
Controls for Germany II were ascertained from the population-based Heinz 
Nixdorf Recall Study.7 Study protocols were reviewed and approved in advance by 
Institutional Review Boards of the participating institutions. All subjects provided 
written informed consent. This includes a clause that all data may be shared with 
collaborating partners such as the PGC. However, consents do not include permission 
for depositing of de-identified individual GWAS genotype and phenotype data into 
the NIMH genetics initiative repository, although these data may be used in specific 
collaborations for studies of neuropsychiatric disorders. All subjects were genotyped 
using the Illumina platform. 
The controls for Germany III were recruited at the Max Planck Institute of 
Psychiatry in Munich, Germany, and were selected randomly from a Munich-based 
community sample. They were collected in the course of genetic studies of major 
depression, and were therefore screened for the presence of anxiety and affective 
disorders using the Composite International Diagnostic Screener (WHO-CIDI). Only 
individuals negative for the above-named disorders were included in the sample. All 
included controls were Caucasian, 93.04% were of German origin. These subjects 
thus represent a group of healthy individuals with regard to depression and anxiety. 
The study was approved by the ethics committee of the Ludwig Maximilians 
University in Munich, Germany, and written informed consent was obtained from all 
subjects.  
 
Australia sample 
Subjects were ascertained through two studies: (a) a bipolar disorder pedigree 
sample (described in McAuley et al)8 and (b) a specialized Sydney Black Dog Institute 
bipolar disorder clinic sample (described in Mitchell et al 2009).9 All subjects were 
interviewed by trained research staff using the DIGS or SCID, using best-estimate 
DSM-IV diagnoses derived from those instruments, medical records and FIGS. First, 
for the pedigree sample, only one bipolar disorder subject per family was included in 
the case sample. Pedigrees were only included in the original genetic study if there 
was unilineal inheritance, and at least two bipolar disorder subjects including at least 
one with bipolar I disorder. Subjects were ascertained through clinical presentations 
to the Mood Disorders Unit at the Prince of Wales Hospital in Sydney, direct referrals 
from Australian clinicians, and bipolar disorder consumer organizations. Second, for 
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the clinic sample, subjects comprised consecutive subjects referred by psychiatrists 
or general practitioners for specialized clinical review. All patients provided written 
informed consent to participate in this study and the study was approved by the local 
ethics committee. Patients were included in the BOMA study and genotyped at the 
Life & Brain Centre in Bonn.   
Australia controls were drawn from families participating in the Brisbane 
Longitudinal Twin Study, an unselected community sample recruited to take part in 
studies of melanoma risk factors, cognition, and other phenotypes. Subjects were not 
screened for any phenotype relevant to bipolar disorder. The study was approved by 
the ethic committee and all proband gave written informed consent. All subjects 
were genotyped as a single project by deCODE and have been through an extensive 
QC process including exclusion for non-European ancestry. The sample is 
overwhelmingly of northern European origin, predominately from the British Isles.   
 
France sample 
Patients with bipolar disorder and controls were recruited as part of a large study on 
genetics of bipolar disorder in France (Paris-Creteil, Bordeaux, Nancy) with a protocol 
approved by relevant IRBs and with written informed consent. Cases were of French 
descent for more than three generations and were all been assessed by a 
well-trained psychiatrist or psychologist with the DIGS10 and the FIGS. Diagnoses 
were based on structured interviews supplemented by medical case notes, mood 
scales and a self-rating questionnaire assessing dimensions. Genotyping of controls 
were provided by the Centre National de Génotypage (M Lathrop, Evry). Patients and 
controls were genotyped on the Illumina platform (HumanHap300, HumanHap550, 
HumanHap 610-quad).  
 
Sweden I sample 
SBP Bipolar cases were recruited from St. Göran’s Hospital in Stockholm, Sweden. All 
participants provided written informed consent to participate in a genetic study of 
bipolar disorder, and the study was approved by the Regional Ethics Committee of 
Stockholm. Diagnoses were based on physician administered ADE11 and MINI.12  
Bipolar disorder cases were identified from the Swedish Bipolar Quality 
Assurance Registry. Patient information within the registry includes disease 
sub-classification, psychosis, age at onset, number of manic and depressive episodes, 
number of hospitalizations and family history. Participants provided written informed 
consent to participate in a genetic study of psychiatric disease, and the study was 
approved by the Regional Ethics Committee of Stockholm.   
Hospital Discharge Registry (HDR) bipolar cases were identified from the Swedish 
Hospital Discharge Registry if they a) have at least two admissions with discharge 
diagnoses of bipolar disorder and b) were born in Sweden or another Nordic country. 
The register contains a nearly complete record of all individuals hospitalized in 
Sweden since 1973. Diagnoses were established by an attending physician and were 
shown to have high sensitivity and specificity.13 The study was approved by the 
Regional Ethics Committee of Stockholm. All participants provided written informed 
consent to participate in genetic studies of psychotic disorders and were interviewed 
by a research nurse about other medical conditions.   
8 
 
The SBP bipolar disorder cases were recruited from the Stockholm County 
catchment area. All patients provided written informed consent to participate in a 
genetic study of bipolar disorder, and the study was approved by the Regional Ethics 
Committee of Stockholm. Diagnoses were made according to the DSM-IV criteria.  
Sweden control samples were obtained from the Swedish Hospital Discharge 
Registry on the condition they had never received discharge diagnoses of bipolar 
disorder, schizophrenia and/or schizoaffective disorder.  
 
Sweden II sample 
This sample consisted of 1415 patients with bipolar disorder (62.5% female, age ± s.d. 
= 53 ± 14, bipolar disorder type I =578, bipolar disorder type II= 517, NOS=281, SAB = 
39, unknown subtype = 4), and 1271healthy controls (50.3% female, age ± s.d.= 59 ± 
11 years). All subjects were unrelated to each other and ethnically Swedish. Patients 
with bipolar disorder were collected from the Swedish National Quality Assurance 
Registry for bipolar disorder (BipoläR), to which all patients with a DSM-IV diagnosis 
of bipolar I, II, NOS, or schizoaffective disorder are considered for registration at the 
participating clinics.14 There were no other inclusion or exclusion criteria. Diagnoses 
were made by the treating physician with longitudinal access to all available clinical 
information. Controls were also identified from national population registers, and 
had never received a discharge diagnosis of SCZ or bipolar disorder. Controls were 
contacted directly in a similar procedure as the cases, gave written informed consent, 
were interviewed about other medical conditions and visited their family doctor or 
local hospital laboratory for blood donation. Patients and controls were genotyped 
on the Illumina Omni Express array, and the genomic inflation factor (lambda) is 1.03. 
 
Iceland sample 
The Iceland sample consisted of 541 subjects with bipolar disorder and 34,546 
population controls. Patients and controls were Icelandic and were recruited 
throughout the country. Diagnoses were assigned according to RDC through the use 
of the SADS-L for 303 subjects. DSM-IV BD diagnoses were obtained through the use 
of the Composite International Diagnostic Interview (CIDI-Auto) for 82 subjects. In 
addition, there were 150 subjects with ICD-9 or ICD-10 bipolar disorder diagnoses 
and nine subjects with DSM-III bipolar disorder diagnoses.   
The 34,546 controls were recruited as a part of various genetic programs at 
deCODE and were not screened for psychiatric disorders. Approval for the study was 
granted by the National Bioethics Committee of Iceland and the Icelandic Data 
Protection Authority and written informed consent was obtained for all participants. 
 
Romania sample 
All patients were recruited from consecutive hospital admissions and were directly 
interviewed with the Structured Clinical Interview for DSM-IV-TR-Axis I Disorders - 
Patient Version (SCID-I, 1994) and the Diagnostic Interview for Genetic Studies (DIGS) 
version 3.0 (1999). Information provided by medical records and interviews of family 
members was also used in a best estimate procedure of diagnosis on the basis of 
DSM-IV-TR criteria. The control sample was population-based, drawn from the same 
population as the patients, and was screened for major psychiatric disorders. The 
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ethnicity of the patients and control subjects was determined by genealogical 
investigation to the grandparental generation. Only the patient sample was 
previously reported in other collaborative studies.15-17 The 174 controls were 
genotyped on Illumina OMNI-Express chips in Bonn, and the patients were also 
genotyped on Illumina chips (partly on Quad Omni-1). 
 
China sample 
The patients who met DSM-IV criteria for bipolar disorder type 1or type 2 were 
recruited from the Division of Mood Disorders at Shanghai Mental Health Center, 
Shanghai Jiao Tong University School of Medicine between November 2006 and 
October 2010. Each patient was independently interviewed and diagnosed by a 
consensus of at least two experienced psychiatrists. Diagnoses were further 
confirmed with an Extensive Clinical Interview and a Structured Clinical Interview for 
DSM-IV Axis/Disorders, Patient Version (SCID-P) given by a research psychiatrist. 
Subjects with comorbid diagnosis of other psychiatric disorders or chronic physical 
illness were excluded in this study to mitigate the potential for compounding factors 
during our analysis. The Extensive Clinical Interview contains items to assess 
demographics, mental status, and ages at onset for the bipolar disorder patients. To 
avoid the biases due to the low reliability of retrospective evaluation of prodromal 
symptoms, we defined age at onset as the first reliably diagnosed hypo/manic or 
depressive episode according to DSM-IV criteria. 
Control subjects were enrolled from hospital staff and students of the School of 
Medicine in Shanghai that were interviewed by a specialized psychiatrist with SCID-P. 
Subjects with any psychiatric disorder and chronic physical disease were excluded 
from our analysis. All subjects were of Han Chinese origin and provided written 
informed consent before any study-related procedures were performed. This sample 
has been reported in a previous study.18 
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Replication-II sample information (see Table DS1) 
UK sample 
The cases consisted of 1218 individuals of which 29% were male. The mean age of 
recruitment was 46 (s.d.=12) years, with a mean age at first impairment because of 
bipolar disorder of 22 (s.d.=9) years. A lifetime diagnosis was made according to 
Research Diagnostic Criteria and the 1218 individuals were categorized as follows: 
bipolar I disorder/mania: 63% cases, bipolar II disorder/hypomania: 29% cases, 
schizoaffective disorder, bipolar type: 8% cases. Of those individuals for whom we 
were able to make a definite rating, 65% of the cases had a lifetime experience of 
psychotic symptoms (defined as a score over 9 on the Bipolar Affective Disorder 
Dimension Scale (BADDS)) and 25% had a lifetime experience of predominantly 
mood-incongruent psychotic symptoms (defined as a score over 29 on the BADDS 
mood incongruence scale). There were 2913 controls in the independent sample, of 
which 47% were male. This sample has been reported in a previous study.19 
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Analysis of hippocampal volume and cognitive performance 
To analyse hippocampal volume, we used the data from a recent large-scale GWAS 
conducted by the Enhancing Neuro Imaging Genetics through Meta-Analysis 
(ENIGMA) consortium.20 The GWAS comprised 17 samples of European ancestry of 
which genome-wide SNP data and hippocampal volume data were collected, 
including a total of 5,775 young healthy individuals (mean age: 34.8 years). Evidence 
for potential association was assessed using the allelic dosage of the SNP and 
covariates controlling for population stratification (four MDS components), 
intracranial volume, age, age2, sex and the interactions between age and sex, and 
age2 and sex. Detailed information on the samples, imaging procedures, genotyping 
methods and statistical analysis can be found in the original GWAS report.20 
For cognitive analysis, we utilized a Chinese sample that included 342 healthy 
Chinese college students from Beijing Normal University who had self-reported no 
known history of any neurological or psychiatric disorders (197 females and 145 
males, aged 18-23). Cognitive and behavioral measures included working memory, 
executive functions (as assessed with the Attention Network Test, the Wisconsin Card 
Sorting Task, and a reversal learning test), and motivation traits etc. Detailed 
cognitive functions examined in this study are listed in Table DS2. This cognitive 
sample was previously used in several studies and shown to be effective in detecting 
authentic risk effects.21-23 Genotyping was performed by Affymetrix 6.0 array using 
standard protocols. Since homozygotes for the rs6088662 minor allele (GG) are rare 
in this sample, we combined GG and GA genotypes as a single group denoted ‘G 
carrier’, and statistical analysis using two-tailed t-test was done with SPSS 16.0 (SPSS, 
Chicago, USA). This particular experiment was approved by the Institutional Review 
Board of the State Key Laboratory of Cognitive Neuroscience and Learning at Beijing 
Normal University, China. Written consent form was obtained from all participants 
following a full explanation of the study procedure. 
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Table DS1 Description of individual samples included in this study 
Sample Cases Case diagnosis Diagnosis Interview Controls Genotyping λ Ref. 
Discovery         
PGC1 7,481 BPD1,BPD2,SAB,BPD-NOS DSMIIR,DSM-IV,RDC multiple 9,250 multiple 1.15 24 
Replication-I         
Germany II 181 BPD1,BPD2 DSM-IV AMDP 527 Illumina 1.05 17,25 
Germany III 490 BPD1,BPD2,SAB,BPD-NOS DSM-IV SCID-I,SADS-L 880 Illumina 1.00 17,25 
Australia 330 BPD1,BPD2,SAB,BPD-NOS DSM-IV SCID,DIGS 1,811 Illumina 1.00 9,26 
France 451 BPD1,BPD2,BPD-NOS DSM-IV DIGS 1,631 Illumina 1.03 27,28 
Sweden I 836 BPD1,BPD2,BPD-NOS DSM-IV ADE,MINI 2,093 Affymetrix 6.0 1.07 27 
Sweden II 1,415 BPD1,BPD2,SAB,BPD-NOS DSM-IV / 1,271 Affymetrix 6.0 1.03 14 
Iceland 541 BPD1,BPD2,BPD-NOS DSM-IV,ICD-10, CID-I,SADS-L 34,426 Affymetrix 6.0 1.11 17 
Romania 244 BPD1 DSM-IV SCID-I-P/DIGS 174 Illumina / 15-17 
China 350 BPD1,BPD2 DSM-IV SCID-P 888 SNaPShot / 18 
Total 4,838    43,701    
Replication-II         
UK 1,218 BPD1,BPD2,SAB RDC / 2,913 ImmunoChip 1.02 19 
Grand Total 13,537    55,864    
BPD1, bipolar disorder type 1; BPD2, bipolar disorder type 2; BPD-NOS, bipolar disorder not otherwise specified; 
SCZ, schizophrenia; SAB, schizoaffective disorder (bipolar type); λ = genomic control lambda. 
 
We primarily used the Illumina (San Diego, CA, USA), Affymetrix and SNaPShot platforms to genotype rs6088662. 
For the genotyping in UK and Romania samples we used proxy SNP rs13041792 in UK (r2=1.00 with rs6088662 in 
Europeans using data from 1000-Human-Genome) and rs6088667 in Romania samples (r2=0.90 with rs6088662) 
instead, as rs6088662 is not covered. 
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Table DS2 Cognitive performance assessment in Chinese sample 
Domain Task Brief description Index 
Memory Wechsler Memory Scale 
-3rd Edition (WMS-III) 
Two subscales: Picture recall (Subjects were showed pictures of 20 simple 
objects for 30 seconds and then asked to recall as many as possible) and picture 
recognition (Subjects were showed pictures of 8 simple objects for 30 seconds 
and then asked to pick them out from 28 pictures).  
Number of items 
correctly recalled 
or recognized 
Working memory In the 2-back working memory task, subjects judged whether the current item 
was the same (or related) to the one presented two trials earlier. Three sessions 
involved morphological, phonological, and semantic judgment. 
Overall accuracy 
Executive 
function 
Attention network test Subjects saw several small arrows on the computer screen and had to judge the 
direction of the arrow in the middle (left or right). The 6 peripheral arrows can 
either in the same or inverse direction to the middle one. There were also cues 
to alert subjects or point to the position where arrows will be presented 
Alert, 
orientation, 
conflict 
Wisconsin card sort task Subjects had to select one from four cards that fits a rule. Rules included color, 
form, and amount of items on the cards, and rules changed during the 
experiment 
Preserved error 
(Nelson) 
Personality Temperament and 
Character Inventory-Re 
7 aspects of personality: Novelty Seeking, Harm Avoidance, Reward 
Dependence, Persistence, Self-Directedness, Cooperativeness, 
Self-Transcendence 
7 subscales 
scores 
Language 
abilities 
Visual-auditory learning, 
from Woodcock Reading 
Mastery test Revised, 
Forms G. 
This task consists of several sessions. In each session, subjects were asked to 
learn a few symbol-word pairs. Afterwards, they were asked to read out some 
sentences written in symbols using corresponding words they just learned.  
Number of 
correct 
responses 
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Table DS3 Results of integrative analysis using brain eQTL and bipolar disorder GWAS 
data 
Gene Gene LBF Gene p-val SNP Location Proximity eQTL p-val BPD p-val SNP LBF 
GLT8D1 6.78 2.22e-06       
   rs2251219 3:52559827 cis 2.84e-17 5.45e-07 6.95 
   rs17073273 6:144330243 trans 8.55e-06 0.73 -0.093 
   rs2070968 10:73251566 trans 6.20e-06 0.67 -0.075 
         
CXCL16 6.16 2.22e-06       
   rs12634640 3:187552259 trans 6.92e-07 1.63e-03 2.38 
   rs810517 10:80612626 trans 1.14e-06 2.12e-04 3.78 
         
TRPC4AP 5.57 8.89e-06       
   rs9883745 3:133715013 trans 2.86e-06 0.46 -0.13 
   rs10501340 11:55439371 trans 6.73e-06 2.75e-02 0.28 
   rs11049310 12:28100068 trans 8.31e-06 0.77 -0.056 
   rs6088662 20:33011294 cis 5.44e-09 5.85e-05 5.48 
         
TAF11 5.52 1.11e-05       
   rs4482754 4:87230328 trans 7.57e-06 3.62e-06 4.40 
   rs7263316 20:19632036 trans 5.94e-07 2.37e-02 1.12 
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   Table DS4 Association of rs2251219 with gene expression in 3p21.1 region 
Author (Ref.) Myers et al1 Unpublished data 
Colantuoni et 
al29 Webster et al
30 Zou et al31 Heinzen et al32 
Region Brain DLPFC DLPFC Brain Cerebellar Temporal cortex Frontal cortex 
Dx (Number) Control (N=193) Control (N=320) Control  (N=261) 
Control + AD 
(N=369) AD (N=176) AD (N=197) AD (N=202) Control  (N=93) 
STAB1 n.s. / n.s. n.s. n.s. n.s. n.s. 0.095 
NT5DC2 / / n.s. / / n.s. n.s. n.s. 
PBRM1 / n.s. 0.085 / / n.s. n.s. n.s. 
GNL3 / / 0.017 / / n.s. n.s. / 
GLT8D1 <1.0×10-16 n.s. 0.048 <1.0×10-30 <1.0×10-18 n.s. n.s. n.s. 
SPCS1 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
NEK4 / 0.051 n.s. / / n.s. n.s. n.s. 
ITIH1 / / n.s. / / n.s. n.s. 0.055 
ITIH3 / / n.s. / / n.s. n.s. n.s. 
ITIH4 <1.0×10-3 / <1.0×10-2 <1.0×10-4 <1.0×10-2 n.s. n.s. n.s. 
TMEM110 / 0.083 / / / n.s. n.s. n.s. 
   N.A., not available; Dx, diagnosis; AD, Alzheimer’s disease; n.s., not significant; DLPFC, Dorsolateral prefrontal cortex 
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   Table DS5 Replication of trans eQTL association in different samples   
Author (Ref.) Myers et al1 Unpublished data 
Colantuoni et 
al29 Webster et al
30 Zou et al31 Heinzen et al32 
Region Brain DLPFC DLPFC Brain Cerebellar Temporal cortex Frontal cortex 
Dx (Number) Control (N=193) Control (N=320) 
Control  
(N=261) 
Control + AD 
(N=369) 
AD 
(N=176) 
AD 
(N=197) AD (N=202) 
Control  
(N=93) 
CXCL16 rs12634640 <1.0×10-6 n.s. n.s. <1.0×10-2 n.s. n.s. n.s. n.s. 
 rs810517 <1.0×10-5 n.s. n.s. 0.023 n.s. n.s. n.s. n.s. 
          
TAF11 rs4482754 <1.0×10-5 / n.s. <1.0×10-2 n.s. n.s. n.s. n.s. 
      Dx, diagnosis; AD, Alzheimer’s disease; n.s., not significant; DLPFC, Dorsolateral prefrontal cortex
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   Table DS6 Association of rs6088662 with gene expression in 20q11.22 region 
Author (Ref.) Myers et al1 Unpublished data 
Colantuoni et 
al29 Webster et al
30 Zou et al31 Heinzen et al32 
Region Brain DLPFC DLPFC Brain Cerebellar Temporal cortex Frontal cortex 
Dx (Number) Control (N=193) Control (N=320) Control  (N=261) 
Control + AD 
(N=369) AD (N=176) AD (N=197) AD (N=202) Control  (N=93) 
AHCY n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
ITCH n.s. 0.067 n.s. n.s. n.s. n.s. n.s. n.s. 
DYNLRB1 / n.s. n.s. / / n.s. n.s. n.s. 
PIGU / n.s. n.s. / / n.s. n.s. n.s. 
NCOA6  n.s. 0.036 n.s. n.s. n.s. n.s. n.s. 
GGT7 <1.0×10-7 <1.0×10-8 0.054 <1.0×10-7 <1.0×10-2 n.s. <1.0×10-2 0.13 
ACSS2 / n.s. 0.098 / / <1.0×10-2 <1.0×10-5 n.s. 
GSS n.s. / n.s. n.s. n.s. n.s. n.s. n.s. 
MYH7B n.s. n.s. <1.0×10-3 n.s. n.s. <1.0×10-15 n.s. n.s. 
TRPC4AP <1.0×10-8 <0.005 / <1.0×10-8 0.023 n.s. n.s. n.s. 
EDEM2 0.040 0.067 <1.0×10-2 <1.0×10-2 0.010 n.s. n.s. n.s. 
PROCR / / n.s. / / n.s. n.s. n.s. 
MMP24 / 0.098 n.s. /  n.s. n.s. 0.11 
UQCC1 / n.s. n.s. / / n.s. n.s. n.s. 
   N.A., not available; Dx, diagnosis; AD, Alzheimer’s disease; n.s., not significant; DLPFC, Dorsolateral prefrontal cortex 
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Table DS7 Association of rs6088662 with GGT7 exon expression in Heinzen et al32 
Probe_Type Gene_Symbol Transcript Transcript_Probe_ID Exon_Probe_ID Start End P-val 
transcript GGT7 NM_178026 3903598 - 32884010 32924318 0.128 
exon GGT7 NM_178026 3903598 3903603 32896517 32896683 0.2386 
exon GGT7 NM_178026 3903598 3903604 32896819 32896919 0.4164 
exon GGT7 NM_178026 3903598 3903606 32901439 32901524 0.02122 
exon GGT7 NM_178026 3903598 3903610 32902247 32902276 0.2765 
exon GGT7 NM_178026 3903598 3903611 32902349 32902375 0.2827 
exon GGT7 NM_178026 3903598 3903613 32902716 32902761 0.2265 
exon GGT7 NM_178026 3903598 3903614 32902789 32902817 0.2122 
exon GGT7 NM_178026 3903598 3903616 32903626 32903723 0.07463 
exon GGT7 NM_178026 3903598 3903618 32903901 32903942 0.08682 
exon GGT7 NM_178026 3903598 3903619 32903951 32903990 0.6926 
exon GGT7 NM_178026 3903598 3903620 32906001 32906080 0.2708 
exon GGT7 NM_178026 3903598 3903621 32906278 32906381 0.5625 
exon GGT7 NM_178026 3903598 3903623 32908286 32908357 0.6493 
exon GGT7 NM_178026 3903598 3903624 32910932 32911062 0.8358 
exon GGT7 NM_178026 3903598 3903626 32911433 32911460 0.05013 
exon GGT7 NM_178026 3903598 3903629 32911733 32911766 0.1856 
exon GGT7 NM_178026 3903598 3903633 32912864 32912890 0.1768 
exon GGT7 NM_178026 3903598 3903634 32912953 32913023 0.5577 
exon GGT7 NM_178026 3903598 3903636 32914307 32914408 0.2789 
exon GGT7 NM_178026 3903598 3903638 32914781 32914926 0.7815 
exon GGT7 NM_178026 3903598 3903643 32924120 32924243 0.938 
exon GGT7 NM_178026 3903598 3903644 32924280 32924317 0.2398 
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Table DS8 Association of rs6088662 with schizophrenia and major depression 
Disorder Sample Cases Controls Allele P-value Odds ratio 95% CI 
Schizophrenia PGC233 35,476 46,839 G 0.0037 1.04 1.00-1.08 
Depression PGC134 9,240 9,519 G 0.27 1.03 0.98-1.08 
 
PsyCoLaus 
study35 
1,301 1,689 G 0.90 0.99 0.88-1.12 
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Table DS9 SNPs in the LD area with potentially functional role on genes 
SNP Position Distance (bp) R2 MAF Function Gene Name 
rs3746444 33041912 30618 0.848 0.20 ncRNA MIR499A 
rs7268266 33045550 34256 0.898 0.20 cds-synon MYH7B 
rs3746436 33049854 38560 0.898 0.20 cds-synon MYH7B 
rs3746435 33050859 39565 0.898 0.20 missense MYH7B 
rs36003887 33052768 41474 0.898 0.20 cds-synon MYH7B 
rs8501 33054245 42951 0.898 0.20 3’ UTR TRPC4AP 
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Table DS10 Association of rs6088662 with hippocampal volume in Europeans20 
SNP Position Allele Frequency β (mm3) SE (mm3) P-value 
rs6088662 20:33547633 G 0.1937 27.29 7.99 0.00063 
SE, standard error; β represents the difference in hippocampal volumes per copy increase of effect 
allele. 
The association analysis in 5,775 healthy European subjects was corrected for intracranial volume, sex, 
age, age2, sex × age, sex × age2 and four MDS components. 
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Table DS11 Association analysis between rs6088662 and cognitive performance in 
the Chinese sample 
 
Cognitive function Test or subscale 
Mean (s.d.) 
t P-value 
G carrier TT 
Executive function Attention alert 0.013 (0.027) 0.0047 (0.025) 2.612 0.0094 
Language abilities Visual-auditory 124.81 (7.76) 121.73 (10.56) 2.539 0.012 
 
Before performing two-tailed t-test, F-test was conducted to compare the variances between two 
genotype groups.  
 
F-test in the analysis of visual-auditory was significant (p<0.005), i.e., assuming the two groups do not 
have equal standard deviations, thus we used unpaired t-test with Welch’s correction.  
 
F-test in the analysis of attention alert was not significant (p>0.3), i.e., assuming both groups have the 
same standard deviation, we used unpaired t-test with no correction.  
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Fig. DS1 Association of rs6088662 with TRPC4AP mRNA expression in Europeans in 
Dimas et al study (n=75).4 
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Fig. DS2 Association of rs6088662 with TRPC4AP mRNA expression in Europeans in 
Nica et al study (n=160).3 
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Fig. DS3 Association of rs6088662 with TRPC4AP mRNA expression in Europeans in 
Stranger et al study (n=109).5 
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Fig. DS4 Spatial expression profiling of GGT7 (A) and TRPC4AP (B) in human tissues. 
The results in brain tissues were marked in red rectangle. 
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